Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) will be announcing its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same period last year, the firm earned $0.11 earnings per share. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Aquestive Therapeutics Stock Performance
AQST stock traded down $0.09 on Tuesday, reaching $3.73. The company’s stock had a trading volume of 347,983 shares, compared to its average volume of 1,961,240. The business has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $3.31. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.
Wall Street Analyst Weigh In
Check Out Our Latest Report on AQST
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Articles
- Five stocks we like better than Aquestive Therapeutics
- Transportation Stocks Investing
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
- 3 Warren Buffett Stocks to Buy Now
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.